ATE169675T1 - Modifizierter menschlicher tumornekrosisfaktor- alpha-rezeptor - Google Patents

Modifizierter menschlicher tumornekrosisfaktor- alpha-rezeptor

Info

Publication number
ATE169675T1
ATE169675T1 AT91918343T AT91918343T ATE169675T1 AT E169675 T1 ATE169675 T1 AT E169675T1 AT 91918343 T AT91918343 T AT 91918343T AT 91918343 T AT91918343 T AT 91918343T AT E169675 T1 ATE169675 T1 AT E169675T1
Authority
AT
Austria
Prior art keywords
pct
tnf alpha
necrosis factor
tumor necrosis
human tumor
Prior art date
Application number
AT91918343T
Other languages
English (en)
Inventor
Marc Feldmann
Avenue Lurgan
Patrick William Gray
Martin J Turner
Med Campus Dr West
Fionula Mary Brennan
Lurgan Avenue Centre
Original Assignee
Kennedy Rheumatology Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE169675(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kennedy Rheumatology Inst filed Critical Kennedy Rheumatology Inst
Application granted granted Critical
Publication of ATE169675T1 publication Critical patent/ATE169675T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT91918343T 1990-10-18 1991-10-18 Modifizierter menschlicher tumornekrosisfaktor- alpha-rezeptor ATE169675T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022648A GB9022648D0 (en) 1990-10-18 1990-10-18 Polypeptide and its use

Publications (1)

Publication Number Publication Date
ATE169675T1 true ATE169675T1 (de) 1998-08-15

Family

ID=10683931

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91918343T ATE169675T1 (de) 1990-10-18 1991-10-18 Modifizierter menschlicher tumornekrosisfaktor- alpha-rezeptor

Country Status (9)

Country Link
US (2) US5633145A (de)
EP (1) EP0556207B2 (de)
JP (1) JPH06504192A (de)
AT (1) ATE169675T1 (de)
DE (1) DE69129990T3 (de)
DK (1) DK0556207T4 (de)
ES (1) ES2121789T5 (de)
GB (1) GB9022648D0 (de)
WO (1) WO1992007076A1 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
EP0486526B2 (de) 1989-08-07 2001-03-07 Peptech Limited Bindeligande für tumornekrosisfaktor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE69333027T2 (de) * 1992-03-30 2004-05-06 Immunex Corp., Seattle Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
CA2249206A1 (en) * 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU4462600A (en) * 1999-04-12 2000-11-14 Agensys, Inc. Novel prostate-restricted gene expressed in prostate cancer
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6537540B1 (en) * 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
EP1939300A1 (de) 1999-05-28 2008-07-02 Targeted Genetics Corporation Verfahren und Zusammensetzung zur Senkung des Spiegels des Tumornekrosefaktors (TNF) bei TNF-assoziierten Leiden
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1263788A2 (de) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identifizierung einer domäne in der familie der tumornekrose-faktor rezeptoren, die die anordnung des rezeptors vor der ligandbindung und sein funktion vermittelt
WO2001064889A2 (en) 2000-03-02 2001-09-07 Xencor Tnf-alpha variants for the treatment of tnf-alpha related disorders
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
JP2007502327A (ja) 2003-05-13 2007-02-08 デピュイ スパイン、インコーポレイテッド 椎間板変性症の治療法
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2005058237A2 (en) * 2003-12-10 2005-06-30 Advanced Biotherapy, Inc. Treatment of aids
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
CA2613494A1 (en) * 2005-06-24 2007-01-04 Michael Lenardo Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (plad) of tumor necrosis factor receptors
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
WO2007058894A2 (en) * 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
WO2007149115A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
PT2068889T (pt) 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
KR101278690B1 (ko) * 2009-10-19 2013-06-24 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
EP2507267B1 (de) * 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Zusammensetzungen und verfahren zur erhöhung der serumshaltbarkeit von fc-fusionsproteinen
US20110187776A1 (en) * 2010-02-01 2011-08-04 Poly-America, L.P. Multiple Inkjet Cannon Printing System
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
DK2825208T3 (en) 2012-03-14 2017-09-11 Levicept Ltd P75NTR-NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) 2015-03-19 2015-05-06 Levicept Ltd Fusion protein
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US20220153827A1 (en) 2019-01-15 2022-05-19 Janssen Biotech, Inc. Anti-TNF Antibody Compositions and Methods for the Treatment of Juvenile Idiopathic Arthritis
KR20210118878A (ko) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
EP3938390A1 (de) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
EP3972690A4 (de) 2019-05-23 2023-07-05 Janssen Biotech, Inc. Verfahren zur behandlung einer entzündlichen darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha
MA56026A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
JP2022536279A (ja) 2019-06-03 2022-08-15 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
IL309997A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs

Also Published As

Publication number Publication date
EP0556207A1 (de) 1993-08-25
DK0556207T4 (da) 2006-02-27
JPH06504192A (ja) 1994-05-19
DE69129990T3 (de) 2006-07-13
GB9022648D0 (en) 1990-11-28
WO1992007076A1 (en) 1992-04-30
DE69129990T2 (de) 1998-12-24
US5633145A (en) 1997-05-27
DE69129990D1 (de) 1998-09-17
EP0556207B2 (de) 2005-11-16
EP0556207B1 (de) 1998-08-12
US5863786A (en) 1999-01-26
ES2121789T3 (es) 1998-12-16
ES2121789T5 (es) 2006-05-01
DK0556207T3 (da) 1999-05-17

Similar Documents

Publication Publication Date Title
DE69129990D1 (de) Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
ATE279205T1 (de) Lösliche lymphotoxin-beta -rezeptoren, antikörper gegen den lymphotoxinrezeptor und ligand- antikörper als therapeutische reagenzien in der behandlung von immunkrankheiten
DE69333950D1 (de) Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
ATE290595T1 (de) Gamma-heregulin
KR100271382B1 (en) Human receptor h4-1bb
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
ATE192045T1 (de) Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
EA199900559A1 (ru) Замещенные, азотсодержащие гетероциклы в качестве ингибиторов протеинкиназы p38
ATE486937T1 (de) Chimärische heteromultimerische adhesine
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
DK0760661T3 (da) Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
DK14587A (da) Anvendelse af specifikke n-methyl-d-aspartat-receptorantagonister til undgaaelse af og behandling af neurodegeneration
ATE395081T1 (de) Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum
NO910232D0 (no) Anordning ved stol.
DK0609280T3 (da) Humane IL-3 varianter
ATE158183T1 (de) Arzneimittel zur behandlung von anxietas
DE69625877D1 (de) Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
DK1283217T3 (da) Antistoffer mod IL-8-receptoren og deres terapeutiske anvendelser
DE59209728D1 (de) VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
EP0959899A4 (de) LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
DE59813016D1 (de) Cadherin derived growth factor und seine verwendung

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification

Ref document number: 0556207

Country of ref document: EP

REN Ceased due to non-payment of the annual fee